DE60239207D1 - Gnrh-agonistische kombinationsmittel - Google Patents

Gnrh-agonistische kombinationsmittel

Info

Publication number
DE60239207D1
DE60239207D1 DE60239207T DE60239207T DE60239207D1 DE 60239207 D1 DE60239207 D1 DE 60239207D1 DE 60239207 T DE60239207 T DE 60239207T DE 60239207 T DE60239207 T DE 60239207T DE 60239207 D1 DE60239207 D1 DE 60239207D1
Authority
DE
Germany
Prior art keywords
drugs
gnrh agonist
combination
gnrh
qol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239207T
Other languages
English (en)
Inventor
Shuichi Furuya
Masami Kusaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60239207D1 publication Critical patent/DE60239207D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
DE60239207T 2001-08-10 2002-08-08 Gnrh-agonistische kombinationsmittel Expired - Lifetime DE60239207D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001244616 2001-08-10
PCT/JP2002/008130 WO2003015820A1 (fr) 2001-08-10 2002-08-08 Medicaments combines d'agoniste de la gnrh

Publications (1)

Publication Number Publication Date
DE60239207D1 true DE60239207D1 (de) 2011-03-31

Family

ID=19074519

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239207T Expired - Lifetime DE60239207D1 (de) 2001-08-10 2002-08-08 Gnrh-agonistische kombinationsmittel

Country Status (7)

Country Link
US (3) US20050215528A1 (de)
EP (1) EP1424080B1 (de)
JP (1) JP2003137814A (de)
AT (1) ATE498408T1 (de)
CA (1) CA2458452C (de)
DE (1) DE60239207D1 (de)
WO (1) WO2003015820A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015820A1 (fr) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
CN1662260B (zh) 2002-06-25 2010-04-28 武田药品工业株式会社 缓释组合物的制备方法
EP1553074B1 (de) 2002-08-12 2014-06-18 Takeda Pharmaceutical Company Limited Kondensiertes benzolderivat und verwendung
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0307777D0 (en) * 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
JP2004344035A (ja) * 2003-05-21 2004-12-09 Kureha Chem Ind Co Ltd 担子菌の乾燥方法
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
WO2005072746A1 (ja) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x受容体阻害剤
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
WO2005105052A1 (en) 2004-05-04 2005-11-10 Hormos Medical Ltd. Novel oral formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
PT1753417E (pt) * 2004-06-07 2012-07-05 Univ Tennessee Res Foundation Um modulador selectivo de receptor de androgénio e as suas utilizações medicinais
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
EP1931322B1 (de) * 2005-09-07 2012-08-15 Merck Serono SA Ikk-hemmer zur behandlung von endometriose
JP5133071B2 (ja) * 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
JP5363344B2 (ja) * 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CA2698822A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Minigastrin as a therapeutic agent
JP5937297B2 (ja) * 2010-03-01 2016-06-22 キヤノンアネルバ株式会社 金属窒化膜、該金属窒化膜を用いた半導体装置、および半導体装置の製造方法
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
AU2013203600C1 (en) 2012-07-13 2016-11-24 University Of Tennessee Research Foundation A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP2909164A1 (de) 2012-10-19 2015-08-26 Fermion Oy Verfahren zur herstellung von ospemifen
EP3801378A4 (de) 2018-05-24 2022-02-23 Celanese EVA Performance Polymers LLC Implantierbare vorrichtung zur verzögerten freisetzung einer makromolekularen wirkstoffverbindung
JP2021524841A (ja) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
DE3586053D1 (de) * 1984-08-02 1992-06-17 Labrie Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1997040846A1 (en) * 1996-04-30 1997-11-06 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
US20020019346A1 (en) * 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
HUP0003194A3 (en) * 1997-08-15 2003-03-28 Cephalon Inc West Chester Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
US6740634B1 (en) * 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
US6573289B1 (en) * 1998-04-23 2003-06-03 Takeda Chemical Industries, Ltd. Naphthalene derivatives, their production and use
DE19833786A1 (de) * 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2339368A1 (en) * 1998-08-07 2000-02-17 Endorecherche, Inc. Inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
DE60027034T2 (de) * 1999-10-22 2006-11-09 Takeda Pharmaceutical Co. Ltd. 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
EP1297850B1 (de) * 2000-07-05 2015-08-19 Takeda Pharmaceutical Company Limited Medizinische zusammensetzungen zur behandlung von mit sexualhormonen verbundenen erkrankungen
JP4121268B2 (ja) * 2000-11-20 2008-07-23 武田薬品工業株式会社 イミダゾール誘導体、その製造法および用途
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
WO2002087616A1 (fr) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Remedes contre la recurrence postoperative du cancer du sein chez les femmes en premenopause
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
WO2003015820A1 (fr) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
CA2466659A1 (en) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents

Also Published As

Publication number Publication date
EP1424080B1 (de) 2011-02-16
CA2458452C (en) 2011-04-19
ATE498408T1 (de) 2011-03-15
US20050215528A1 (en) 2005-09-29
WO2003015820A1 (fr) 2003-02-27
US20100286063A1 (en) 2010-11-11
US20070179097A1 (en) 2007-08-02
JP2003137814A (ja) 2003-05-14
EP1424080A4 (de) 2004-09-01
CA2458452A1 (en) 2003-02-27
EP1424080A1 (de) 2004-06-02

Similar Documents

Publication Publication Date Title
DE60239207D1 (de) Gnrh-agonistische kombinationsmittel
TW200517126A (en) Mesothelioma therapeutic agent
ATE469897T1 (de) Indazolcarbonsäureamidverbindungen
EA200800618A1 (ru) Комбинация снотворного агента длительного действия и снотворного агента короткого действия
TW200531679A (en) Methods of modulating cytokine activity; related reagents
HUP0302544A3 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
HK1066534A1 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
EP1606264A4 (de) Monocyclische anilidspirohydantoine als cgrp-rezeptorantagonisten
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
CL2008002886A1 (es) Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
AU2003256410A8 (en) Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions
CR8495A (es) Tratamiento de osteoporosis relacionado con terapia con inhibidor de aromatasa
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
ATE439828T1 (de) In der mundhíhle dispergierbare feste pharmazeutische form
DK1778622T3 (da) Para-alkyl-substituerede N-(4-hydroxy-3-methoxy-benzyl)-kanelsyreamider og anvendelse deraf til fremstilling af lægemidler
TW200503667A (en) Therapeutic combinations
DE50006420D1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
GEP201606538B (en) Preoperative treatment of post operative pain